CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
5.38
+0.02 (0.37%)
At close: Oct 27, 2025, 4:00 PM EDT
5.37
-0.01 (-0.19%)
After-hours: Oct 27, 2025, 4:41 PM EDT
CureVac Revenue
CureVac had revenue of 1.25M EUR in the quarter ending June 30, 2025, a decrease of -91.38%. This brings the company's revenue in the last twelve months to 510.51M, up 675.15% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
510.51M EUR
Revenue Growth
+675.15%
P/S Ratio
2.02
Revenue / Employee
519,338 EUR
Employees
983
Market Cap
1.21B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 535.18M | 481.42M | 895.54% |
| Dec 31, 2023 | 53.76M | -13.66M | -20.26% |
| Dec 31, 2022 | 67.42M | -35.57M | -34.54% |
| Dec 31, 2021 | 102.99M | 54.12M | 110.74% |
| Dec 31, 2020 | 48.87M | 31.46M | 180.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CVAC News
- 26 days ago - CureVac: The Hidden Value Of The mRNA Wallet - Seeking Alpha
- 2 months ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Accesswire
- 2 months ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 4 months ago - CureVac Announces Voting Results of General Meeting - Accesswire
- 4 months ago - Top Stock Movers Now: Oracle, Boeing, CureVac, and More - Investopedia
- 4 months ago - BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
- 4 months ago - BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising. - Barrons
- 4 months ago - BioNTech to acquire CureVac in $1.25 billion all-stock deal - Reuters